The combination of AstraZeneca's Calquence and AbbVie/Roche's Venclexta has become the first all-oral, fixed-duration regimen for patients with newly-diagnosed chronic lymphocytic leukaemia (CLL) in ...
Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...
Clonal B-cell–mediated hypogammaglobulinemia is common (up to 85%) and can coexist with qualitative immune defects that blunt vaccine responses and protection against encapsulated bacteria. T-cell ...
CLL is a type of leukemia where the bone marrow makes too many white blood cells. Treatment can help to slow the progression of the cancer and ease a person’s symptoms. CLL treatments include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results